Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Machiels

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.
British Journal of Cancer|November 11, 2010
Cancer and renal insufficiency results of the BIRMA studyN Janus, V Launay-Vacher, E Byloos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2009
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinomaC M Nutting, C M L van Herpen, A B Miah, et al.
Human Gene Therapy|April 21, 1999
Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopeniaJ P Machiels, A S Govaerts, T Guillaume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neckS Schmitz, M Hamoir, H Reychler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2015
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC studyJ Guigay, J Fayette, A F Dillies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 28, 2020
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>P Bossi, A T Chan, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2015
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neckJ-P Machiels, P Specenier, J Krauß, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neckN Honoré, C van Marcke, R Galot, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.
British Journal of Cancer|November 11, 2010
Cancer and renal insufficiency results of the BIRMA studyN Janus, V Launay-Vacher, E Byloos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2009
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinomaC M Nutting, C M L van Herpen, A B Miah, et al.
Human Gene Therapy|April 21, 1999
Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopeniaJ P Machiels, A S Govaerts, T Guillaume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neckS Schmitz, M Hamoir, H Reychler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2015
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC studyJ Guigay, J Fayette, A F Dillies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 28, 2020
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>P Bossi, A T Chan, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2015
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neckJ-P Machiels, P Specenier, J Krauß, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neckN Honoré, C van Marcke, R Galot, et al.
Pageof 7